News

MS Patients Treated in Clinical Practice with Fingolimod Show Benefits

New research evaluating fingolimodā€™s clinical efficacy, safety, and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS) largely supported its use, finding that the oral drugā€™s efficacy in a real-world settingĀ was comparable to results observed in Phase 3Ā clinical studies. The research article, ā€œEfficacy and Safety of Fingolimod in an Unselected…

MS Progression Halted Using Stem Cells Derived from Gum Tissue

A new source of stem cells, the mesenchymal stem cells (MSCs) isolated from the human periodontal ligament (hPDLSCs), offers a potential treatmentĀ capable of halting multiple sclerosis (MS) progression. The study, ā€œAlternative source of stem cells derived from human periodontal ligament: a new treatment for experimental autoimmune encephalomyelitis,ā€ was published…

MS Patients and Caregivers Invited to Take Part in Meditation Study

A new randomizedĀ andĀ controlled trial is recruiting multiple sclerosis (MS) patients to investigate the effect of a mindfulness-based telemedicine intervention program on patients and their caregivers. The clinical study’sĀ protocol was recently published in the journal Trials,Ā titled “A telemedicine meditation intervention for people with multiple sclerosis…

Rise in MS and Autoimmune Disease Linked to Processed Foods

In a new study, researchers found that additives common to processed foods can damage the tight junctions that protect the intestinal mucosa, and which are essential to theĀ intestinalĀ tolerance and immunity balance that works to prevent autoimmune diseases such as multiple sclerosis (MS). The article, titled ā€œChanges in…

MS Drug Under Study No Longer Being Given in Higher Doses to Patients

Teva Pharmaceutical Industries Ltd. and Active Biotech have discontinued the use of higher doses of the drug laquinimod in two ongoing multiple sclerosis (MS) studies. The decision was based on a recommendation byĀ the Data Monitoring Committee (DMC)Ā that isĀ supervising the clinical trials afterĀ cardiovascular events, none of which were fatal,…

Multiple Sclerosis Association of America Appoints New President and CEO

The Multiple Sclerosis Association of America (MSAA), a national nonprofit organization and leading resource for the multiple sclerosis (MS) community, recently announced thatĀ Gina Ross MurdochĀ has been namedĀ the association’s new president and CEO. Ms. Murdoch is nowĀ the MSAAā€™s leader in areas comprising strategic progress, programmatic growth, and business development strategies.

Potential Mechanism in MS Pathogenesis Seen in Study

Researchers found that a group of untreated patients with multiple sclerosis (MS) and patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) carry a specific group of hyperactivated immune cells, the inflammatory CD8+ T cells, suggesting a potential common mechanism contributing to disease pathogenesis. The study, ā€œA Preliminary Comparative…

Volunteer Yoga Instructor Helps Multiple Sclerosis Patients

Gail Pickens-BargerĀ is aĀ doTERRAĀ Elite Wellness Advocate who has been helping students to improve their fitness for 15 years. The yoga instructor is now also dedicated to serving the fitness goals of a particular population ā€” patients with multiple sclerosis (MS). MS is aĀ demyelinating diseaseĀ in which the insulating layer (called myelin) that…

New Study Focuses on Sleep Troubles and Quality of Life in MS Patients

A new studyĀ investigated the influence of sleep disturbance, fatigue and disability on the quality of life (QOL) in multiple sclerosis (MS) patients. Health-related QOLĀ measurements are important tools for assessing the impact of a disease on self-reportedĀ physical, mental, emotional, and social functioning. Most studies show that QOL is not related to…

Top 10 Multiple Sclerosis Articles of 2015

Multiple Sclerosis News Today has reported the latest therapies, clinical trial developments, and events in multiple sclerosis (MS) on a daily basis throughout the past year. As 2015 comes to an end, hereĀ are the year’s 10 articlesĀ most widely readĀ byĀ Ā Multiple Sclerosis News TodayĀ readers, each with a brief summary of the developments…

Experimental RRMS Therapy to Be Tested in a Phase 2b Clinical Trial

GeNeuro, a company developing therapies for neurological and autoimmune disorders, recently announced the initiation of a Phase 2b clinical trial to assess its lead investigational antibody GNbAC1 in patients with relapsing-remitting multiple sclerosis (RRMS). The trial, called ā€œCHANGE-MS,ā€ plans to enroll 260 patients across 68 centers acrossĀ theĀ European Union and…

MS Researchers to Be Among 200 Specialists at January Symposium on Glial-Neuronal Interactions

The upcoming 9thĀ annual ā€œGlial-neuronal Interactions in Health and Diseaseā€ symposium will bring together nearlyĀ 200 neuroscientistsĀ ā€” focused onĀ neuron and glial cell interaction and its affect on diseases such as multiple sclerosis (MS) ā€” to discuss the latest findings in this area of brain research. The daylong symposium is to be held…

MS Patients Using New Web-based Program to Manage and Integrate Care

A team of researchers from the Netherlands haveĀ developed an interactive web-based program called MSmonitor that offers multiple sclerosis patients a way to manage and better integrate the multidisciplinary care they require.Ā Pilot data from a study of its useĀ is detailed in the article,Ā ā€œThe interactive web-based program MSmonitor for…

MS Physical Therapy in Need of Proper Study, Experts Say

The National Multiple Sclerosis SocietyĀ announced that a panel of expertsĀ led a comprehensive review of 142 published studies addressing rehabilitation in multiple sclerosis (MS), and found evidence suggesting that weekly in-home or outpatient physical therapy offers benefits ā€” but, mostly, it found a lack of well-designed studies into…